转换酶抑制剂对冠状动脉粥样硬化性心脏病患者心率变异性的影响  

The impact of converting enzyme inhibitor on heart rate variability in eoronary heart disease patients

作　　者：吴小玉[1] 易慧[2] 许明芳[3] 

机构地区：[1]宜宾市第二人民医院ICU,644000 [2]广州市中山大学附属第一医院ICU,528000 [3]宜宾县人民医院,644600

出　　处：《中国保健营养（下半月）》2010年第11期72-73,共2页China Health Care & Nutrition

摘　　要：目的 探讨转换酶抑制剂对冠状动脉粥样硬化性心脏病患者心率变异性的临床疗效。方法选择我院2008年2月至2009年10月收治冠状动脉粥样硬化性心脏病患者68例随机分为两组，洛汀新组34例与对照组34例进行疗效分析。结果洛汀新组与对照组HRV比较，洛汀新组ST段偏移较对照组轻，心律失常发生数明显低于对照组（P〈0．05）。结论转换酶抑制剂能改善自主神经失衡提高HKV外，还可增加左室射血分数减慢心率，降低心肌耗氧量且能阻止心室重构纠正细胞内低钾低镁，降低心肌死后恶性心律失常的发生率，值得推广应用。Objective ： To investigate clinical efficacy of converting enzyme inhibitor on heart rate variability in coronary heart disease patients .Methods ： 68 coronary heart disease patients from February 2008 to October 2009 were involved in this study. They were randomly divided into treatment group and control group, each were 34 cases. Benazepril were given in the treatment group.Results ： The heart rate variability was improved in the benazepril group, ST segment deviation was decreased. And the frequency of arrhythmia in the treatment group was reduced significantly （P〈0.05） .Conclusion ： Converting enzyme inhibitor can improve autonomic imbalance and heart rate variability, increase left ventricular ejection fraction, also decrease heart rate and myocardial oxygen consumption, prevent left ventricular remodeling and reduce the incidence of malignant arrhythmia.

关 键 词：心率变异 转换酶抑制剂 冠状动脉粥样硬化性心脏病 

分 类 号：R322.1[医药卫生—人体解剖和组织胚胎学]